Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611361 · ClinicalTrials.gov registry record
Wound Imaging Study to Gather Clinical References for a Device to Assist Selecting Level-of-amputation in PAD Patients
A clinical trial, sponsored by SpectralMD.
- Terminated
- Registry status
- 55
- Enrollment target
NCT03611361: Clinical Trial study, sponsored by SpectralMD.
NCT03611361 is a clinical trial that was terminated before completion, run by SpectralMD. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03611361 was terminated before completion, sponsored by SpectralMD.
- TERMINATED
- Registry status
- 55 participants
- Enrollment target
Study Summary
This is a proof-of-concept study to collect images to train a CADe algorithm to predict the correct level of amputation in individuals scheduled for amputation secondary to PAD.
Primary Outcome
Healing as indicated by: re-epithelialization of tissue within the incision site and no signs of drainage/exudate.
Interventions
- DEVICE SpectralMD DeepView Wound Imaging System 2.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-11-18 |
| Est. Completion | 2020-12 |
Why NCT03611361 stopped before completion
NCT03611361 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SpectralMD DeepView Wound Imaging System 2.0 is the first listed.
NCT03611361 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03611361 about?
NCT03611361 is a clinical study titled "Wound Imaging Study to Gather Clinical References for a Device to Assist Selecting Level-of-amputation in PAD Patients". This is a proof-of-concept study to collect images to train a CADe algorithm to predict the correct level of amputation in individuals scheduled for amputation secondary to PAD.
What is the current status of trial NCT03611361?
This trial is currently terminated. The enrollment target is 55 participants. The study started on 2015-11-18. Estimated completion is 2020-12.
What interventions are being tested in trial NCT03611361?
The interventions under investigation include: SpectralMD DeepView Wound Imaging System 2.0 (DEVICE).
Who is sponsoring clinical trial NCT03611361?
This trial is sponsored by SpectralMD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI